The latter is only as good as the information being fed with mediocre comprehension and interpretation skills.
Correction: very mediocre, because they cannot work out that a large lender will of course, seek to preserve the company as a going concern especially if it considers the commercial opportunity real and significant.
In the rush to denigrate, they forget key commercial considerations.
We're not talking top shelf questions and analysis with our whytee.
Cell Therapy News/Articles, page-16852
-
- There are more pages in this discussion • 969 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.030(2.52%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $5.184M | 4.406M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 194493 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 49214 | 12 |
View Market Depth
| Last trade - 15.17pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |